UBS has initiated coverage on Waystar Holding Corp (WAY) with a Buy rating, marking the firm's first assessment of the company. This decision reflects UBS's analysis of Waystar's business fundamentals and growth prospects within the healthcare software industry.
Headquartered in Lehi, Utah, Waystar Holding Corp provides healthcare organizations with essential cloud software aimed at simplifying payment processes. The company employs 1,500 full-time staff and went public on June 7, 2024. Its enterprise-grade platform, Waystar, leverages advanced algorithms and internally developed artificial intelligence to enhance billing accuracy and reduce costs for healthcare providers.
As of December 11, 2025, Waystar's market capitalization stands at $7.1 billion, with a trailing P/E ratio of 63.51 and earnings per share of $0.62. Upcoming earnings reports are scheduled for July 28, 2026, with an estimated EPS of $0.42 and revenue of $326.5 million.
Analyst ratings, such as UBS's Buy designation, offer insights based on extensive research and financial modeling. However, investors are reminded that these ratings should be one of many factors considered in the decision-making process, as they can change over time with new information.
The consensus among analysts as of December 1, 2025, indicates a majority view of Buy, with 7 Strong Buy, 15 Buy, 2 Hold, and no Sell or Strong Sell ratings. Recent actions from other firms include Barclays maintaining an Overweight rating and Freedom Capital Markets initiating coverage with a Hold rating.
This update provides insight into Waystar's positive reception in the market and its strategic position within the healthcare sector.